| Literature DB >> 24941136 |
Lisette van der Meer1, Marte Swart2, Jorien van der Velde3, Gerdina Pijnenborg4, Durk Wiersma5, Richard Bruggeman6, André Aleman7.
Abstract
BACKGROUND: Patients with schizophrenia often experience problems regulating their emotions. Non-affected relatives show similar difficulties, although to a lesser extent, and the neural basis of such difficulties remains to be elucidated. In the current paper we investigated whether schizophrenia patients, non-affected siblings and healthy controls (HC) exhibit differences in brain activation during emotion regulation.Entities:
Mesh:
Year: 2014 PMID: 24941136 PMCID: PMC4062465 DOI: 10.1371/journal.pone.0099667
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic information for the healthy controls, siblings and patients.
| Demographic information | Controls (N = 20) | Siblings (N = 20) | Patients (N = 20) |
| Age (mean ± SD) | 35.5±11.7 | 32.6±8.6 | 35.2±10.8 |
| Gender (n male) | 14 | 11 | 16 |
| Level of education (mean ± SD) | 5.9±0.9 | 6.0±0.8 | 5.7±1.0 |
| Age of Illness onset (mean ± SD) | n.a. | n.a. | 24.7±8.1 |
| PANSS positive (mean ± SD) | n.a. | n.a. | 14.7±5.4 |
| PANSS negative (mean ± SD) | n.a. | n.a. | 14.7±4.1 |
| PANSS general (mean ± SD) | n.a. | n.a. | 29.9±7.7 |
| Medication (n) | none | none | Aripirazole (7) |
| Citalopram (3) | |||
| Clomipranine (1) | |||
| Clozapine (2) | |||
| Fluoxetine (2) | |||
| Haldol (1) | |||
| Mirtazapine (1) | |||
| Olanzapine (9) Oxazepam (3) | |||
| Paroxetine (1) | |||
| Perfenazine (1) | |||
| Quetiapine (3) | |||
| Risperidone (1) | |||
| Temazepam (1) | |||
| Venlafaxine (1) |
Groups were compared with an analysis of variance (ANOVA) and did not differ significantly (p = 0.62).
Level of education was defined according to scoring system of Verhage [57] (ordinal scale). Group differences for gender and education were tested with a chi-square and kruskal-wallis test, respectively. Neither gender (p = 0.23) nor level of education (p = 0.72) differed between groups.
Figure 1Experimental design for a single trial.
The task consisted of 110 trials (22 neutral and 88 negative). A single trial lasted 15,5 seconds. Every 9 or 10 trials were followed by a fixation cross of 20 seconds.
Mean scores on questionnaires and on the emotion regulation task for healthy controls, siblings and patients.
| Controls (N = 19) | Siblings (N = 20) | Patients (N = 20) | |
| Mean ± SD | Mean ± SD | Mean ± SD | |
| Tasks and questionnaires | |||
| ERQ | |||
| Reappraisal | 5.0±1.0 | 4.6±1.0 | 4.4±1.3 |
| Suppression | 2.9±1.2 | 3.1±.09 | 3.5±1.1 |
| Rating Emotion Regulation | |||
| Attend negative | 2.3±0.5 | 2.6±0.6 | 2.7±0.6 |
| Reappraise | 1.9±0.6 | 2.2±0.5 | 2.4±0.7 |
| Suppress | 2.1±0.6 | 2.5±0.6 | 2.4±0.6 |
| Attend neutral | 1.1±0.1 | 1.1±0.1 | 1.3±0.2 |
For one subject, no behavioral data for the emotion regulation task were available due to technical problems.
Figure 2Affective ratings for the emotion regulation task per condition.
Lines represent the three groups separately.
Figure 3Activation for HC only during reappraisal.
fMRI results for the contrast Reappraise >Attend negative.
| MNI coordinates | |||||||
| Region of activation | L/R | N voxels | T | Z | x | y | z |
|
| |||||||
| Inferior frontal gyrus (V & DLPFC) | L | 2273 | 7.23 | 6.75 | −38 | 24 | −8 |
| 6.63 | 6.24 | −32 | 28 | −4 | |||
| 5.95 | 5.67 | −50 | 24 | 8 | |||
| Inferior frontal gyrus/insula | R | 135 | 4.57 | 4.43 | 42 | 20 | −12 |
| Superior frontal gyrus (DMPFC) | L | 519 | 5.85 | 5.58 | −6 | 16 | 62 |
| 370 | 5.03 | 4.85 | −6 | 56 | 34 | ||
| 4.49 | 4.36 | −10 | 42 | 48 | |||
| 3.45 | 3.39 | −2 | 38 | 44 | |||
| Superior & Middle Temporal Gyrus (STG/MTG) | L | 1103 | 4.68 | 4.53 | −42 | −54 | 22 |
| 4.39 | 4.26 | −38 | −46 | 22 | |||
| 4.31 | 4.19 | −52 | −50 | 4 | |||
| R | 81 | 4.2 | 4.09 | 58 | −4 | −8 | |
| 3.83 | 3.74 | 56 | 6 | −20 | |||
| Parahippocampal gyrus | L | 327 | 4.36 | 4.24 | −10 | −34 | −2 |
| 4 | 3.91 | −6 | −30 | −10 | |||
| Thalamus | R | 152 | 4.24 | 4.13 | 0 | −14 | 10 |
| 3.19 | 3.14 | 10 | −8 | 4 | |||
| Caudate | L | 58 | 3.87 | 3.78 | −12 | 4 | 12 |
| R | 57 | 4.24 | 4.13 | 12 | 16 | 6 | |
| Posterior cingulate gyrus | L | 32 | 3.5 | 3.44 | −4 | −48 | 28 |
| 3.27 | 3.22 | −2 | −56 | 22 | |||
|
| |||||||
| Inferior frontal gyrus/insula | L | 24 | 3.66 | 3.59 | −38 | 22 | −10 |
| Middle temporal gyrus (MTG) | L | 37 | 3.95 | 3.86 | −38 | −66 | 26 |
| Parahippocampal gyrus | L | 44 | 3.98 | 3.89 | −12 | −34 | 0 |
| Caudate | R | 31 | 4.14 | 4.03 | 8 | 20 | 6 |
| Thalamus | R | 24 | 3.51 | 3.44 | 2 | −14 | 8 |
|
| |||||||
| Superior temporal gyrus (STG) | L | 109 | 4.22 | 4.11 | −44 | 8 | −18 |
| Inferior frontal gyrus (IFG) | 3.7 | 3.62 | −40 | 18 | −14 | ||
| Parahippocampal gyrus/amygdala | L | 96 | 3.84 | 3.76 | −16 | −4 | −18 |
| 3.5 | 3.43 | −22 | 2 | −18 | |||
| 3.49 | 3.42 | −18 | −14 | −20 | |||
| L | 51 | 3.69 | 3.62 | −10 | −34 | −2 | |
|
| |||||||
| Middle frontal gyrus | R | 20 | 3.42 | 3.36 | 42 | 4 | 40 |
|
| |||||||
| Inferior parietal lobe (IPL) | L | 66 | 4.23 | 4.12 | −38 | −70 | 28 |
| Caudate | L | 41 | 3.56 | 3.49 | −14 | 14 | 4 |
| 3.47 | 3.4 | −6 | 8 | 2 | |||
| R | 23 | 3.93 | 3.84 | 12 | 18 | 6 | |
L, Left; R, Right; MNI, Montreal Neurological Institute; ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DMPFC, dorsomedial prefrontal cortex; VLPFC, ventrolateral prefrontal cortex.
fMRI results for the contrast Attend negative>Suppress.
| MNI coordinates | |||||||
| Region of activation | L/R | N voxels | T | Z | x | y | z |
|
| |||||||
| Lingual gyrus | L | 190 | 4.01 | 3.91 | −16 | −70 | 4 |
| 3.60 | 3.53 | −14 | −78 | 4 | |||
| Middle Occipital gyrus | L | 229 | 3.86 | 3.78 | −36 | −74 | 30 |
| 3.79 | 3.71 | −30 | −66 | 38 | |||
| 3.40 | 3.34 | −20 | −64 | 48 | |||
L, Left; R, Right; MNI, Montreal Neurological Institute.
Figure 4Group comparisons during reappraisal.
A) HC versus schizophrenia patients. B) HC versus non affected siblings. C) Non-affected siblings versus schizophrenia patients.